Current Medical Therapy for Chronic Inflammatory Bowel Diseases

Surgical Clinics of North America

Volumn 87, Issue 3, 2007, Pages 697-725

  Tamboli, Cyrus P ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CORTICOTROPIN; CYCLOSPORIN; FOLIC ACID; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; OLSALAZINE; PREDNISOLONE; PREDNISONE; RIFAXIMIN; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; ACNE; ADRENAL SUPPRESSION; ALLERGY; ALOPECIA; ANAPHYLAXIS; ANOREXIA; ANUS FISTULA; ANXIETY; ARTHRALGIA; AVASCULAR NECROSIS; BACKACHE; BONE MARROW SUPPRESSION; BRONCHITIS; CANCER; CATARACT; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CLOSTRIDIUM DIFFICILE; COLITIS; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; CYSTITIS; DEMYELINATING DISEASE; DIABETES MELLITUS; DIARRHEA; DIET THERAPY; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; DYSPNEA; DYSURIA; ECG ABNORMALITY; EDEMA; ENTERITIS; ESOPHAGOGASTRODUODENOSCOPY; EXFOLIATIVE DERMATITIS; FATIGUE; FEVER; FLU LIKE SYNDROME; GINGIVA HYPERPLASIA; GINGIVITIS; GROWTH RETARDATION; HAIR LOSS; HEADACHE; HEMOLYSIS; HEPATITIS; HEPATITIS B; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INCREASED APPETITE; INFECTION; INJECTION SITE IRRITATION; INSOMNIA; INTERSTITIAL NEPHRITIS; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; LEUKOPENIA; LIVER FIBROSIS; LIVER TOXICITY; LOADING DRUG DOSE; LOW FAT DIET; LUNG TOXICITY; LUPUS ERYTHEMATOSUS; LUPUS LIKE SYNDROME; LYMPHOMA; MALAISE; MALE INFERTILITY; MEGALOBLASTIC ANEMIA; META ANALYSIS; MOOD CHANGE; MOON FACE; MULTIPLE SCLEROSIS; MUSCLE CRAMP; MYALGIA; MYCOSIS; MYOCARDITIS; MYOPATHY; NAUSEA; NAUSEA AND VOMITING; NEPHRITIS; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OLIGOSPERMIA; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; OSTEOPOROSIS; PANCREATITIS; PANCYTOPENIA; PARESTHESIA; PERICARDITIS; PHARYNGITIS; PHOTOSENSITIVITY; PLEURA EFFUSION; PRIORITY JOURNAL; PROCTITIS; PROCTOCOLECTOMY; PSEUDOMEMBRANOUS COLITIS; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; REMISSION; RESPIRATORY TRACT INFECTION; REVIEW; SEIZURE; SIDE EFFECT; STEVENS JOHNSON SYNDROME; STOMATITIS; STRIA; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; TENDON RUPTURE; TOXIC EPIDERMAL NECROLYSIS; TREMOR; TUBERCULOSIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

CHRONIC DISEASE; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; REMISSION INDUCTION;

EID: 34249995188     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2007.03.014     Document Type: Review

References (120)

1. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19 Suppl A (2005) 5-36
2. Kane S.V. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 23 5 (2006) 577-585
3. Dubinsky M.C. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2 9 (2004) 731-743
4. Best W.R., Becktel J.M., and Singleton J.W. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 77 4 Pt 2 (1979) 843-846
5. Malchow H., Ewe K., Brandes J.W., et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 86 2 (1984) 249-266
6. Summers R.W., Switz D.M., Sessions Jr. J.T., et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 77 4 Pt 2 (1979) 847-869
7. Ursing B., Alm T., Barany F., et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's Disease Study in Sweden. II. Result. Gastroenterology 83 3 (1982) 550-562
8. Azad Khan A.K., Piris J., and Truelove S.C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2 8044 (1977) 892-895
9. Singleton J.W., Hanauer S.B., Gitnick G.L., et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology 104 5 (1993) 1293-1301
10. Hanauer S.B., and Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2 5 (2004) 379-388
11. Tremaine W.J., Schroeder K.W., Harrison J.M., et al. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 19 4 (1994) 278-282
12. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 3 7 (2006) 390-407
13. Colombel J.F., Lemann M., Cassagnou M., et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 94 3 (1999) 674-678
14. Rosen A., Ursing B., Alm T., et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's Disease Study in Sweden. I. Design and methodologic considerations. Gastroenterology 83 3 (1982) 541-549
15. Sutherland L., Singleton J., Sessions J., et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 32 9 (1991) 1071-1075
16. Gerard L., Garey K.W., and DuPont H.L. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 3 2 (2005) 201-211
17. Prantera C., Lochs H., Campieri M., et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 23 8 (2006) 1117-1125
18. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4 5 (2006) 621-630
19. Greenberg G.R., Feagan B.G., Martin F., et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 331 13 (1994) 836-841
20. Tremaine W.J., Hanauer S.B., Katz S., et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 97 7 (2002) 1748-1754
21. Thomsen O.O., Cortot A., Jewell D., et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med 339 6 (1998) 370-374
22. Present D.H., Meltzer S.J., Krumholz M.P., et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 111 8 (1989) 641-649
23. Chun A., Chadi R.M., Korelitz B.I., et al. Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-up. Inflamm Bowel Dis 4 3 (1998) 177-181
24. Fernandez-Banares F., Cabre E., Esteve-Comas M., et al. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. JPEN J Parenter Enteral Nutr 19 5 (1995) 356-364
25. O'Morain C., Segal A.W., and Levi A.J. Elemental diet as primary treatment of acute Crohn's disease: a controlled trial. Br Med J (Clin Res Ed) 288 6434 (1984) 1859-1862
26. Giaffer M.H., North G., and Holdsworth C.D. Controlled trial of polymeric versus elemental diet in treatment of active Crohn's disease. Lancet 335 8693 (1990) 816-819
27. Mansfield J.C., Giaffer M.H., and Holdsworth C.D. Controlled trial of oligopeptide versus amino acid diet in treatment of active Crohn's disease. Gut 36 1 (1995) 60-66
28. Verma S., Brown S., Kirkwood B., et al. Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial. Am J Gastroenterol 95 3 (2000) 735-739
29. Suzuki H., Hanyou N., Sonaka I., et al. An elemental diet controls inflammation in indomethacin-induced small bowel disease in rats: the role of low dietary fat and the elimination of dietary proteins. Dig Dis Sci 50 10 (2005) 1951-1958
30. Middleton S.J., Rucker J.T., Kirby G.A., et al. Long-chain triglycerides reduce the efficacy of enteral feeds in patients with active Crohn's disease. Clin Nutr 14 4 (1995) 229-236
31. Sandborn W., Sutherland L., Pearson D., et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2 (2000) CD000545
32. Dubinsky M.C., Reyes E., Ofman J., et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 100 10 (2005) 2239-2247
33. Siegel C.A., and Sands B.E. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther 22 1 (2005) 1-16
34. Feagan B.G., Rochon J., Fedorak R.N., et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 332 5 (1995) 292-297
35. Sands B.E. New therapies for the treatment of inflammatory bowel disease. Surg Clin North Am 86 4 (2006) 1045-1064
36. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 15 (1997) 1029-1035
37. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 7 (2003) 601-608
38. Farrell R.J., Alsahli M., Jeen Y.T., et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124 4 (2003) 917-924
39. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 9317 (2002) 1541-1549
40. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 15 (2001) 1098-1104
41. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 2 (2006) 323-333
42. Hanauer S.B. Crohn's disease: step up or top down therapy. Best Pract Res Clin Gastroenterol 17 1 (2003) 131-137
43. Modigliani R., Colombel J.F., Dupas J.L., et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 110 3 (1996) 688-693
44. Camma C., Giunta M., Rosselli M., et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 113 5 (1997) 1465-1473
45. Greenberg G.R., Feagan B.G., Martin F., et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 110 1 (1996) 45-51
46. Feagan B.G., Fedorak R.N., Irvine E.J., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 342 22 (2000) 1627-1632
47. Pearson D.C., May G.R., Fick G., et al. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2 (2000) CD000067
48. Lichtenstein G.R., Abreu M.T., Cohen R., et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130 3 (2006) 940-987
49. Kandiel A., Fraser A.G., Korelitz B.I., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54 8 (2005) 1121-1125
50. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 9 (2004) 876-885
51. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 1 (2007) 52-65
52. Sandborn W.J., Hanauer S.B., Rutgeerts P.J., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II Trial. Gut (2007) in press
53. Gelbmann C.M., Rogler G., Gross V., et al. Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease. Am J Gastroenterol 97 6 (2002) 1438-1445
54. Pearson D.C., May G.R., Fick G.H., et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123 2 (1995) 132-142
55. Lecomte T., Contou J.F., Beaugerie L., et al. Predictive factors of response of perianal Crohn's disease to azathioprine or 6-mercaptopurine. Dis Colon Rectum 46 11 (2003) 1469-1475
56. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 18 (1999) 1398-1405
57. Sandborn W.J., Present D.H., Isaacs K.L., et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 125 2 (2003) 380-388
58. Parsi M.A., Lashner B.A., Achkar J.P., et al. Type of fistula determines response to infliximab in patients with fistulous Crohn's disease. Am J Gastroenterol 99 3 (2004) 445-449
59. Caprilli R., Gassull M.A., Escher J.C., et al. European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 55 Suppl 1 (2006) i36-i58
60. Cottone M., and Camma C. Mesalamine and relapse prevention in Crohn's disease. Gastroenterology 119 2 (2000) 597
61. Ardizzone S., Maconi G., Sampietro G.M., et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 127 3 (2004) 730-740
62. Van Assche G., and Rutgeerts P. Medical management of postoperative recurrence in Crohn's disease. Gastroenterol Clin North Am 33 2 (2004) 347-60
63. D'Haens G., Sandborn W.J., Feagan B.G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132 2 (2007) 763-786
64. Truelove S.C., and Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 2 4947 (1955) 1041-1048
65. Danish 5-ASA Group. Topical 5-aminosalicylic acid versus prednisolone in ulcerative proctosigmoiditis. A randomized, double-blind multicenter trial. Dig Dis Sci 32 6 (1987) 598-602
66. Marshall J.K., and Irvine E.J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 40 6 (1997) 775-781
67. Sutherland L.R. Topical treatment of ulcerative colitis. Med Clin North Am 74 1 (1990) 119-131
68. Watkinson G. Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate sodium; a controlled trial employing restricted sequential analysis. Br Med J 2 5103 (1958) 1077-1082
69. Truelove S.C., and Hambling M.H. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium; a report on a controlled therapeutic trial. Br Med J 2 5103 (1958) 1072-1077
70. Campieri M., De Franchis R., Bianchi Porro G., et al. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Scand J Gastroenterol 25 7 (1990) 663-668
71. Gross V., Bar-Meir S., Lavy A., et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment Pharmacol Ther 23 2 (2006) 303-312
72. Sutherland L.R., May G.R., and Shaffer E.A. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 118 7 (1993) 540-549
73. Meyers S., Sachar D.B., Present D.H., et al. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology 93 6 (1987) 1255-1262
74. Sninsky C.A., Cort D.H., Shanahan F., et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 115 5 (1991) 350-355
75. Sutherland L., Macdonald J.K., Lennard-Jones J.E., et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2 (2006) CD000543
76. Baron J.H., Connell A.M., Lennard-Jones J.E., et al. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1 (1962) 1094-1096
77. Dick A.P., Grayson M.J., Carpenter R.G., et al. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 5 (1964) 437-442
78. Safdi M., DeMicco M., Sninsky C., et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 92 10 (1997) 1867-1871
79. Hanauer S.B. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther 24 Suppl 3 (2006) 37-40
80. Green J.R., Lobo A.J., Holdsworth C.D., et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. Gastroenterology 114 1 (1998) 15-22
81. Schroeder K.W., Tremaine W.J., and Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317 26 (1987) 1625-1629
82. Hanauer S.B., Sandborn W.J., Kornbluth A., et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 100 11 (2005) 2478-2485
83. Marteau P., Probert C.S., Lindgren S., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54 7 (2005) 960-965
84. Kamm M.A., Sandborn W.J., Gassull M., et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 132 1 (2007) 66-75 [quiz: 432-3]
85. Lennard-Jones J.E., Longmore A.J., Newell A.C., et al. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1 (1960) 217-222
86. Baron J.H., Connell A.M., Kanaghinis T.G., et al. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 2 5302 (1962) 441-443
87. Faubion Jr. W.A., Loftus Jr. E.V., Harmsen W.S., et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121 2 (2001) 255-260
88. Truelove S.C., Willoughby C.P., Lee E.G., et al. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 2 8099 (1978) 1086-1088
89. Truelove S.C., and Jewell D.P. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1 7866 (1974) 1067-1070
90. Bossa F., Fiorella S., Caruso N., et al. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol 102 3 (2007) 601-608
91. Burke D.A., Axon A.T., Clayden S.A., et al. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 4 2 (1990) 123-129
92. Chapman R.W., Selby W.S., and Jewell D.P. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 27 10 (1986) 1210-1212
93. Dickinson R.J., O'Connor H.J., Pinder I., et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 26 12 (1985) 1380-1384
94. Mantzaris G.J., Petraki K., Archavlis E., et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 36 9 (2001) 971-974
95. Gionchetti P., Rizzello F., Ferrieri A., et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci 44 6 (1999) 1220-1221
96. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353 23 (2005) 2442-2449
97. Oren R., Arber N., Odes S., et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 110 5 (1996) 1416-1421
98. Lichtiger S., Present D.H., Kornbluth A., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330 26 (1994) 1841-1845
99. Van Assche G., D'Haens G., Noman M., et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 125 4 (2003) 1025-1031
100. Kornbluth A., Present D.H., Lichtiger S., et al. Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol 92 9 (1997) 1424-1428
101. Carbonnel F., Boruchowicz A., Duclos B., et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci 41 12 (1996) 2471-2476
102. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 23 (2005) 2462-2476
103. Kohn A., Prantera C., Pera A., et al. Infliximab in the treatment of severe ulcerative colitis: a follow-up study. Eur Rev Med Pharmacol Sci 8 5 (2004) 235-237
104. Jarnerot G., Hertervig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 7 (2005) 1805-1811
105. Hyde G.M., Jewell D.P., Kettlewell M.G., et al. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 44 10 (2001) 1436-1440
106. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 99 5 (2004) 878-883
107. Sutherland L., and Macdonald J.K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2 (2006) CD000544
108. Bergman R., and Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 23 7 (2006) 841-855
109. Mantzaris G.J., Hatzis A., Petraki K., et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Colon Rectum 37 1 (1994) 58-62
110. Powell-Tuck J., Buckell N.A., and Lennard-Jones J.E. A controlled comparison of corticotropin and hydrocortisone in the treatment of severe proctocolitis. Scand J Gastroenterol 12 8 (1977) 971-975
111. Timmer A., McDonald J., Macdonald J., et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 1 (2007) CD000478
112. Ardizzone S., Maconi G., Russo A., et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55 1 (2006) 47-53
113. Tamboli C.P., Caucheteux C., Cortot A., et al. Probiotics in inflammatory bowel disease: a critical review. Best Pract Res Clin Gastroenterol 17 5 (2003) 805-820
114. Hurst R.D., Molinari M., Chung T.P., et al. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 131 5 (1996) 497-500 [discussion: 501-2]
115. Shen B., Achkar J.P., Lashner B.A., et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 7 4 (2001) 301-305
116. Gionchetti P., Rizzello F., Venturi A., et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 13 6 (1999) 713-718
117. Mimura T., Rizzello F., Helwig U., et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 16 5 (2002) 909-917
118. Gionchetti P., Rizzello F., Venturi A., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119 2 (2000) 305-309
119. Gionchetti P., Amadini C., Rizzello F., et al. Diagnosis and treatment of pouchitis. Best Pract Res Clin Gastroenterol 17 1 (2003) 75-87
120. Viscido A., Habib F.I., Kohn A., et al. Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. Aliment Pharmacol Ther 17 10 (2003) 1263-1271